[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406539-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-406539-en":123},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","diffuse-large-b-cell-lymphoma-invited-review","Diffuse large B-cell lymphoma - Invited review","","Large B-cell lymphoma is the prototype of aggressive non-Hodgkin lymphomas, driving the highest global burden of lymphoma-related deaths. For decades, treatment aims at cure, evolving from CHOP to rituximab plus CHOP, yet considerable clinical, pathologic, and biologic heterogeneity means not all patients achieve durable remission. Incorporating biologic heterogeneity into decisions is still not routine care, despite advances across frontline and relapsed/refractory settings, including improved PFS with POLARIX.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/diffuse-large-b-cell-lymphoma-invited-review/406539/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/diffuse-large-b-cell-lymphoma-invited-review/406539.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What trial evidence highlights progress in frontline therapy?","Question",{"text":63,"@type":64},"The POLARIX trial demonstrated, for the first time, improved progression-free survival in a prospective randomized phase 3 setting.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},406539,1790826552,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,102,107,112,115,119],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":100,"slug":101},7,40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":104,"show_sort_weight":105,"slug":106},8,"Research & Report",30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":116,"slug":118},10,"Lifestyle","lifestyle",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":89,"slug":122},19,"General","general",{"code":4,"msg":74,"data":124},{"doc_id":71,"user_id":125,"nickname":42,"user_avatar":126,"doc_module":4,"category_id":99,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":108,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":4},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1002/hon.3202  \nINVITED REVIEW  \nDiffuse large B‐cell lymphoma  \nAllison Barraclough1,2 | Eliza Hawkes3,4 | Laurie H. Sehn5 | Sonali M. Smith6   \n1Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia 2University of Melbourne, Medical School, Melbourne, Victoria, Australia  \n3Olivia Newton John Cancer Research Centre, Austin Health, Melbourne, Victoria, Australia 4Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia  \n5BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, British Columbia, Canada  \n6The University of Chicago Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA  \nCorrespondence  \nSonali M. Smith, Section of Hematology/ Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA. Email: [smsmith@bsd.uchicago.edu](smsmith@bsd.uchicago.edu)  \nAbstract  \nLarge B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma‐related deaths. For nearly 4 decades, the goal of treatment has been“cure”, first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic, and biologic heterogeneity, and not all patients are cured. Understanding and incorporating this biologic heterogeneity into treatment decisions unfortunately is not yet standard of care. Despite this gap, we now have significant advances in frontline, relapsed, and refractory settings. The POLARIX trial shows, for the first time, improved progression‐free survival in a prospective randomized phase 3 setting. In the relapsed and refractory settings, there are now many approved agents/regimens, and several bispecific antibodies poised to join the arsenal of options. While chimeric antigen receptor T‐cell therapy is discussed in detail elsewhere, it has quickly become an excellent option in the second‐line setting and beyond. Unfortunately, special populations such as older adults continue to have poor outcomes and be underrepresented in trials, although a new generation of trials aim to address this disparity. This brief review will highlight the key issues and advances that offer improved outcomes to an increasing portion of patients.  \nKEYWORDS  \nantibody‐drug conjugates, diffuse large B‐cell lymphoma, older adults, treatment  \n1 | INTRODUCTION  \nLarge B‐cell lymphoma is a heterogeneous group of lymphomas. The updated World Health Organization (WHO) Classification and International Consensus Classification recognize an expanding group of discrete entities, with diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS) being the most common. 1,2 Within DLBCL, NOS (herein referred to as DLBCL), two molecular subtypes have been recognized by gene expression profiling: germinal‐center B cell‐  \nlike (GCB) and activated B cell‐like (ABC).3 These subtypes represent lymphomas arising from different stages of lymphoid differentiation (cell‐of‐origin) and driven by distinct oncogenic mechanisms.4 While the ABC subtype generally has an inferior outcome (3‐year progression‐free survival (PFS) of approximately 45% versus 75% in the GCB subtype), a higher risk subset within GCB‐DLBCL has been recognized characterized by a high‐grade molecular signature.5,6 Moving beyond cell‐of‐origin, novel DLBCL classifications have been proposed based on detailed genetic analyses.7,8 The LymphGen  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.  \nHematological Oncology. 2024;e3202. [https://doi.or","cbCaimx7t3qe8rzh","https://ap.wps.com/l/cbCaimx7t3qe8rzh","pdf",259106,"English","# Introduction\n## Frontline treatment for diffuse large B-cell lymphoma (DLBCL)\n## Key advances in relapsed and refractory settings","[{\"question\":\"What trial evidence highlights progress in frontline therapy?\",\"answer\":\"The POLARIX trial demonstrated, for the first time, improved progression-free survival in a prospective randomized phase 3 setting.\"}]","Diffuse large B-cell lymphoma - Invited review | PDF",1790566303,23]